Sylvain Chemtob

Biography

Dr. Chemtob is professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University and Director of Ophthalmology Research, Université de Montréal. Dr. Chemtob is a reputed neonatologist and pharmacologist, with expertise on mechanisms implicated in ischemic retinopathies and other conditions involving inflammation including preterm labor. He has also initiated a new technology to develop peptidomimetic drugs that target membrane receptors; some compounds are licensed to industry, and one which successfully completed Phase Ib clinical trial is Phase II-ready (PDC Biotech). His seminal work also triggered the approval (EMEA [2004], FDA [2006]) of new therapies for closure of ductus arteriosus, which is now standard of care. Dr. Chemtob is author of over 250 articles reported in major journals, as well as inventor holding 10 patents. He has trained so far 46 graduate students and 29 post-graduate fellows (MDs and PhDs). He has received numerous awards and is a member of the Canadian Academy of Health Sciences.   Dr. Chemtob is professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University and Director of Ophthalmology Research, Université de Montréal. Dr. Chemtob is a reputed neonatologist and pharmacologist, with expertise on mechanisms implicated in ischemic retinopathies and other conditions involving inflammation including preterm labor. He has also initiated a new technology to develop peptidomimetic drugs that target membrane receptors; some compounds are licensed to industry, and one which successfully completed Phase Ib clinical trial is Phase II-ready (PDC Biotech). His seminal work also triggered the approval (EMEA [2004], FDA [2006]) of new therapies for closure of ductus arteriosus, which is now standard of care. Dr. Chemtob is author of over 250 articles reported in major journals, as well as inventor holding 10 patents. He has trained so far 46 graduate students and 29 post-graduate fellows (MDs and PhDs). He has received numerous awards and is a member of the Canadian Academy of Health Sciences.  

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry